Lantheus Medical Imaging
Clinical trials sponsored by Lantheus Medical Imaging, explained in plain language.
A company developing diagnostic imaging agents.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New scan could reveal hidden spread of prostate cancer Results expected Sep 2026 (estimated)
- New radiation drug targets bone cancer cells directly Results expected Aug 2027 (estimated)
-
New radiation drug targets bone cancer cells directly
Disease control Recruiting nowThis study tests a new drug called LNTH-2403, which delivers radiation directly to cancer cells in people with osteosarcoma (a type of bone cancer) that has returned or not responded to standard treatments. The drug is given as an injection and aims to shrink tumors or slow their…
Phase 1/2 • Sponsor: Lantheus Medical Imaging • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Can a new PET tracer spot hidden prostate cancer spread?
Diagnosis Recruiting nowResearchers are testing a radioactive tracer called gallium-68 LNTH-2401 to see how well it works with PET/CT scans for finding prostate cancer in pelvic lymph nodes. The trial has two parts: first, they find the best dose and scan timing, then they check how accurately the scan …
Phase 2/3 • Sponsor: Lantheus Medical Imaging • Aim: Diagnosis
Last updated Sep 21, 2026 22:00 UTC